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Simple Summary: Prostate cancer cells require androgens to survive and grow. In turn, targeting
androgen signaling has become a predominant therapeutic strategy in this disease. These hormones
regulate a plethora of biological processes, which identification could aid the refinement of future
anticancer treatments. Our aim was to uncover metabolic processes under the control of androgens,
taking advantage of bioinformatics analyses using publicly accessible data in prostate cancer. We
found that these hormones control the abundance of an enzyme, ceramide kinase (CERK). CERK
produces ceramide-1-phosphate, a metabolite with prosurvival and migration properties. This finding
suggests that antiandrogen therapies could be limited by the reactivation of this metabolic process.
Abstract: Prostate cancer (PCa) is one of the most prevalent cancers in men. Androgen receptor
signaling plays a major role in this disease, and androgen deprivation therapy is a common ther-
apeutic strategy in recurrent disease. Sphingolipid metabolism plays a central role in cell death,
survival, and therapy resistance in cancer. Ceramide kinase (CERK) catalyzes the phosphorylation of
ceramide to ceramide 1-phosphate, which regulates various cellular functions including cell growth
and migration. Here we show that activated androgen receptor (AR) is a repressor of CERK expres-
sion. We undertook a bioinformatics strategy using PCa transcriptomics datasets to ascertain the
metabolic alterations associated with AR activity. CERK was among the most prominent negatively
correlated genes in our analysis. Interestingly, we demonstrated through various experimental
approaches that activated AR reduces the mRNA expression of CERK: (i) expression of CERK is
predominant in cell lines with low or negative AR activity; (ii) AR agonist and antagonist repress and
induce CERK mRNA expression, respectively; (iii) orchiectomy in wildtype mice or mice with PCa
(harboring prostate-specific Pten deletion) results in elevated Cerk mRNA levels in prostate tissue.
Mechanistically, we found that AR represses CERK through interaction with its regulatory elements
and that the transcriptional repressor EZH2 contributes to this process. In summary, we identify
a repressive mode of AR that influences the expression of CERK in PCa.
Keywords: prostate cancer; bioinformatics; mouse models; sphingolipid metabolism; ceramide
kinase
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1. Introduction
Hormone signaling governs the molecular activity of an important fraction of cells in
our body. Steroid hormones are essential for the development and function of a wide range
of tissues through the regulation of nuclear receptors, including sexual organ development
and function [1–3]. In male reproductive organs, androgens activate androgen receptors
(AR) to elicit a broad transcriptional program [4]. These steroids induce a conformational
change in AR that promotes its dimerization, translocation to the nucleus, and association
with Androgen Response Elements (ARE) in the DNA [4].
Similar to their normal counterparts, prostate cancer cells require androgen signaling
to survive and proliferate [5–7]. In turn, androgen receptor and androgen synthesis
represent pivotal therapeutic targets (androgen deprivation therapy or ADT), and a variety
of anticancer agents targeting this hormonal program has proven to hamper prostate cancer
progression [7–9]. However, resistance to androgen deprivation often emerges, leading
to a form of the disease (castration-resistant prostate cancer or CRPC) that accounts for a
large fraction of prostate cancer mortality [10–12]. It is therefore essential to deconstruct
the molecular events that account for ADT efficacy and drug resistance.
Due to its relevance in normal and cancer cell homeostasis, the study of AR signaling
has become a focus of research. Many AR targets have been identified and validated, a
process that has advanced exponentially with the implementation of high throughput
genomics and transcriptomics technologies [13–15]. Whereas the vast majority of AR target
genes are transcriptionally activated by androgens, reports point at AR-mediated gene
repression as an emerging phenomenon [16–18].
Metabolic pathways have been consistently reported among the molecular programs
regulated by androgens. Androgens control the uptake and biosynthesis of different
types of lipids and the metabolism of amino acids and carbohydrates [19–24]. However, a
systematic analysis of metabolic routes under androgen regulation is lacking.
Sphingolipids function as second messengers and structural components essential for
cell homeostasis [25,26]. Ceramide is at the core of this metabolic pathway, and its role in
cell biology is widely accepted [26]. Whereas this metabolite activates tumor-suppressive
processes, its phosphorylation and the production of ceramide-1-phosphate (C1P) induces
a switch in its activity, thus promoting cell viability, proliferation, and migration [26].
Ceramide kinase (CERK) catalyzes the production of C1P and, in turn, the regulation of
this enzyme is paramount in sphingolipid homeostasis [25]. Yet, our understanding of the
regulation of CERK in health and disease is limited, and upstream regulatory cues need to
be identified.
Here we annotate the metabolic genes that are consistently correlated with androgen
receptor activity by means of a bioinformatics approach encompassing a compendium
of publicly available PCa transcriptomics datasets, which we term the androgen receptor
metabolic correlome. Among the regulated genes and pathways, we focus on sphingolipid
metabolism and demonstrate that CERK is an AR-repressed gene. We shed light on the
molecular mechanism of action of AR to repress CERK, thus expanding the information
regarding the mechanism and function of androgens.
2. Results
To identify metabolic processes regulated by AR signaling in PCa, we undertook a
bioinformatics approach (Figure 1A). First, we set out to define the gene signature that
would best illustrate the activation status of AR in prostate cancer. We started from a
published meta-analysis of AR signaling-associated gene expression studies, in which the
authors identified a gene set that was consistently regulated by androgens in 6 different
experimental studies [15]. The positive or negative transcriptional activation by AR was
ascertained in that gene set with 34 genes (Table S1). Stemming from the work by Massie
et al. [27], together with Cancertool [28], we could annotate these genes as induced or
repressed by activated AR (Table S1). We identified 23 genes consistently activated by
androgens and 8 that were repressed, whereas 3 genes were excluded from the analysis
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due to the inability to assign directionality. Of note, this shortlist contained well-known AR
target genes, including kallikreins KLK2 and KLK3 [29], thus validating our bioinformatics
strategy.
We built an AR activity gene expression signature based on the ratio of expression
of upregulated and downregulated AR target genes, which we termed AR signature (AR
Signature = (average expression of upregulated genes in Log2) − (average expression of
upregulated genes in Log2); Figure 1A). We next selected the genes identified as metabolic
enzymes and transporters according to KEGG [30] and metabolic co-regulators [31,32],
leading to a gene set of 2775 genes that we defined as metabolic genes. We performed
correlation studies with the metabolic gene set and AR signature in 8 different PCa tran-
scriptomics datasets containing primary tumor specimens. We selected those that exhibited
a consistent correlation, meaning a direct (coefficient greater than 0.2 and p-value lower
than 0.05) or inverse (coefficient lower than −0.2 and p-value lower than 0.05) correlation
in more than 50% of datasets with available data for a given gene [33–40]. This correlation
analysis led to a list of 223 metabolic genes consistently correlated with AR activity, that
we defined as the AR metabolic correlome (Figure 1A; Table S2). As a validation of our
strategy, we could confirm that the top metabolic genes directly correlated with AR activity,
GPT2 and SLC45A3, are reported AR targets [41,42].
To ascertain the metabolic impact of androgen signaling, we performed gene enrich-
ment analyses. KEGG analysis revealed a series of metabolic pathways enriched in the
list of AR correlated genes (Figure 1B). We interrogated the nature and predicted impact
of androgen signaling on the resulting metabolic pathways. Some of these pathways
have been previously reported as androgen-regulated [19–24]. Interestingly, sphingolipid
metabolism exhibited a gene expression alteration by androgens that directed the pathway
towards the production of ceramide (Figure 1C). AR activity is directly correlated with the
expression of enzymes that metabolize sphingolipids to produce ceramide, whereas it is
inversely correlated with ceramide kinase, an enzyme that will reduce the pool of ceramide
by eliciting its phosphorylation [43]. We decided to focus on this metabolic pathway for
subsequent studies, owing to the little information regarding the regulation of the pathway
by androgens. A summary of the correlation results of the AR signature with the mRNA
expression of these enzymes in multiple PCa datasets is depicted in Figure 1D.
Correlation studies based on activity signatures represent an invaluable tool to identify
genes which expression is associated with a pathway of interest. However, this information
is insufficient to conclude that such genes are targets of the process under investigation
as they could be altered as a secondary consequence of downstream molecular effectors.
To ascertain the genes within sphingolipid metabolism that are regulated by androgens,
we performed a variety of in vitro and in vivo experimental approaches. We evaluated the
expression pattern of these candidate genes in a panel of prostate cell lines with known
androgen signaling status. We took advantage of KLK3 (the gene encoding for prostate-
specific antigen, PSA) as a readout of AR activity. As reported, LNCaP, C4-2, 22RV1, and
VCaP cells exhibited robust AR activity by means of KLK3 expression, whereas PC3 and
DU145 (AR-negative prostate cancer cells) or RWPE1, PWR1E, and BPH1 cells (benign
prostate immortalized cells) exhibited low activity of the nuclear receptor (Figure 2A).
Among the five sphingolipid metabolism genes identified in the correlome, only CERK
and PLPP1 exhibited a consistent association with AR activity. PLPP1 exhibited a positive
association with androgen signaling, and CERK expression was reduced in AR-expressing
cells (Figure 2A and Figure S1A). Next, we manipulated the activation status of AR in vitro
with selective agonists (dihydrotestosterone, DHT) or antagonists (MDV3100, Enzalu-
tamide) [44]. The effect of these compounds on the expression of KLK3 was robust 24 hours
after treatment (Figure 2B). Among the five sphingolipid metabolism genes, PLPP1 and
CERK exhibited a significant time-dependent regulation of gene expression after 24 h with
both agents, with the predicted directional consistency (Figure 2B and Figure S1B).
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Figure 1. Sphingolipid metabolism is regulated by androgen receptor (AR). (A) Bioinformatics anal-
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Figure 1. Sphingolipid metabolism is regulated by androgen receptor (AR). (A) Bioinformatics
analysis workflow of prostate cancer patient transcriptomics datasets performed with Cancertool to
identify metabolic genes correlated with androgen receptor activity. (B) KEGG pathways enrich-
ment of AR activity-correlated metabolic genes (AR metabolic correlome). (C) Schematic ceramide
biosynthetic pathway, adapted from Merscher et al. Positively and negatively correlated enzymes are
highlighted in red and blue, respectively. (D) Heatmap representation of the sphingolipid metabolic
genes correlated with AR signature in multiple PCa datasets encompassing primary tumors. Red and
blue color intensity depict the degree of direct and inverse correlation, respectively. An asterisk is
included when the correlation coefficient is greater than 0.2 or lower than −0.2 with a p-value lower
than 0.05.
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Figure 2. AR represses CERK expression. (A) Analysis of the AR target KLK3 and CERK gene expression by qRT-PCR in a 
panel of prostate cells (n = 3 independent experiments). Data were normalized to GAPDH expression. mRNA abundance 
was normalized to the benign cell line PWR1E. Und. stands for undetermined. (B) Analysis of KLK3 and CERK gene ex-
pression by qRT-PCR upon treatment with AR agonist (dihydrotestosterone, DHT, 10 nM, left panels) or antagonist (MDV-
3100, 10 µM, right panels) in LNCaP cells (n = 3 independent experiments). Data were normalized to GAPDH expression. 
ANOVA and Dunnett’s multiple comparisons test was performed. (C) Gene expression analysis of the AR target gene, 
Figure 2. AR represses CERK expression. (A) nalysi of th target KLK3 and CERK gen expression by qRT-PCR in a
panel of prostate cells (n = 3 independent experiments). Data ere normalized to GAPDH expression. mRNA abundance
was normalized to the benign cell line PWR1E. Und. stands for undetermined. (B) Analysis of KLK3 and CERK gene
expression by qRT-PCR upon treatment with AR agonist (dihydrotestosteron , DHT, 10 nM, left panels) or antagonist
(MDV-3100, 10 µM, right panels) in LNCaP cells (n = 3 independent experiments). Data were normalized to GAPDH
expression. ANOVA and Dunnett’s multiple comparisons test was performed. (C) Gene expression analysis of the AR target
gene, Nkx3.1, and Cerk by qRT-PCR in prostate-specific Pten wild type in upper panels (Ptenpc+/+) castrated at 4 months
of age (Cast, n = 7 mice) compared to control (Ctl, n = 9 mice), and knock out mice in lower panels (Ptenpc−/−, castrated
at 6 months of age, n = 6 mice per group), 6 days after performing orchiectomy. Data were normalized to GAPDH/Gapdh
expression. A one-tailed Mann–Whitney test was performed. (D) Pearson correlation of CERK and KLK3 mRNA expression
in the indicated PCa datasets. (E) LC/MS analysis of phosphorylated C24 and C20 ceramide species upon treatment with
AR antagonist MDV-3100 (10 µM) compared to vehicle (Veh). Paired t-test analyses were performed. * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001.
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Androgens control both prostate development and growth [4–6]. To corroborate the
regulation of sphingolipid metabolic genes in a more complex experimental setting, we
performed orchiectomy in adult male mice, in a context of normal prostate physiology
(wildtype mice) or PCa (prostate-conditional Pten knockout mice). As mice do not express
kallikreins, we used the androgen-dependent gene Nkx3.1 to validate the loss of AR activity
after castration (Figure 2C). Among the five genes, only Cerk exhibited the predicted
changes in mRNA levels upon castration (Figure 2C and Figure S1C). We focused our
attention on this enzyme and showed that CERK was repressed by androgen signaling in a
validation set of PCa cell lines (C4-2, VCaP, and 22Rv1) (Figure S2A). Of note, CERK was
less responsive to androgen regulation in 22RV1, a cell line that expresses an AR variant,
and was not regulated in the AR-negative cell line PC3 (Figure S2A,B). These results are in
line with the inverse correlation between the AR target KLK3 and CERK in various PCa
transcriptomics datasets (Figure 2D and Figure S2C). Overall, our results reveal CERK as a
gene repressed by androgen signaling in PCa.
The regulation of CERK expression by androgens should influence the production of
C1P. To evaluate whether AR signaling regulates CERK activity and C1P production, we
measured the abundance of these metabolites in a context of AR inhibition in androgen-
dependent LNCaP cells that exhibit low CERK expression. In agreement with the up-
regulation of CERK observed upon AR inhibition, we detected an increase in C20 and
C24 C1P levels, but not in their non-phosphorylated ceramide counterparts (Figure 2E and
Figure S3). Of note, the levels of sphingosine-1-phosphate, a different sphingolipid not
phosphorylated by CERK, remained unaffected by MDV3100 (Figure S3).
To elucidate the mechanism of repression of CERK, we focused on the regulatory
activity of AR. This nuclear receptor functions predominantly as a transcriptional activa-
tor. However, there are examples of genes repressed by androgen signaling [16,17,45,46].
We performed chromatin immunoprecipitation (ChIP) assays. We studied two potential
androgen receptor binding sites (AR sites) in the proximity of the CERK gene based on a
previous report (Figure 3A) [47]. Only AR site 1 exhibited significant binding to AR, and
androgen stimulation significantly increased the association of the nuclear receptor to this
site (Figure 3B,C). As a quality control of our assay, we gathered two results. First, we
showed that androgens enhanced the binding of AR to the AR sites present in KLK3 by
ChIP (Figure 3C). Second, AR binding to AR site 2 did not show enrichment in the qPCR
analysis, suggesting that the assay did not have technical issues that would artificially
provide binding to CERK (Figure 3B).
The repressive transcriptional activity of AR has been linked to the function of the
chromatin remodeler EZH2 [45], among other factors. We hypothesized that EZH2, the
functional enzymatic component of the Polycomb Repressive Complex 2, could function
as a CERK repressor and that this protein would define the negative regulation of the
sphingolipid metabolic gene by androgens. On the one hand, we showed that EZH2 was
significantly associated with the AR-binding region in CERK AR site 1 (Figure 3D). On the
other hand, we took advantage of a well-characterized inhibitor of EZH2, GSK126 [48].
Treatment with this compound in PCa cells revealed a dose-dependent de-repression of
CERK (Figure 3E). Moreover, the EZH2 inhibitor partially prevented DHT-induced CERK
repression, whereas it cooperated with AR antagonist MDV3100 in the activation of CERK
expression (Figure 3E). Of note, this inhibitor did not exhibit a consistent effect on the
regulation of the AR canonical target KLK3 (Figure S4A), in line with the non-repressive
action of AR on this kallikrein.
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Figure 3. EZH2 cooperates with AR in eliciting CERK repression. (A) Androgen receptor binding site (AR sites) location 
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represented on CERK gene sequ nce. (B) ChIP of AR on the i ated sites in LNCaP cells ( = 8 independent experiments).
Data were normalized to IgG (negative-binding control). One-sample t-test. (C) ChIP of AR on CERK AR site 1 and KLK3
in LNCaP cells (n = 3–5 independent experiments) with and without DHT treatment (10 nM). Data were normalized to IgG
(negative-binding control). One-tail Paired t-test. (D) ChIP of EZH2 on AR site 1 of CERK regulatory region in LNCaP cells
(n = 5 independent experiments). Data were normalized to IgG (negative-binding control). One-sample t-test. (E) Analysis
of CERK gene expression by qRT-PCR upon 24-h treatment with EZH2 inhibitor GSK126 at increasing concentrations (left),
in combination with DHT (10 nM, middle) and MDV-3100 (10 µM, right) in LNCaP cells (n = 3 independent experiments).
ANOVA with Dunnett´s (left) or Tukey´s (center and right) multiple comparison test. The asterisk refers to comparisons
against vehicles, hash refers to comparisons against GSK and dollar refers to comparisons against DHT or MDV. (F) Pearson
correlation of CERK and EZH2 mRNA expression in the indicated PCa datasets. (G) mRNA expression analysis of CERK
and EZH2 in normal tissue (N) and localized PCa (PT) of the indicated patient datasets. One tail Student t-test. * p < 0.05;
** p < 0.01; *** p < 0.001; **** p < 0.0001; ## p < 0.01; #### p < 0.0001; $$ p < 0.01; $$$$ p < 0.0001. n.s., non-significant.
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EZH2 expression is positively associated with PCa pathogenesis and progression [49].
We interrogated whether the regulation of CERK by EZH2 could be a general phenomenon
in this tumor type. To this end, we studied the correlation between CERK and EZH2 mRNA
abundance. Interestingly, we observed an inverse correlation between the expression
of the two genes in various PCa cohorts (Figure 3F and Figure S4B). We then evaluated
whether this regulation could influence the expression of CERK in PCa. Analysis of
available PCa datasets confirmed that EZH2 was predominantly upregulated in localized
PCa compared to normal prostate (Figure 3G), and this phenomenon was associated with a
robust downregulation of CERK in the same datasets. These results strongly suggest that
AR represses CERK, at least in part, through EZH2, and that the epigenetic modifier might
be a general regulator of CERK expression beyond AR.
We and others have previously shown that the product of CERK, C1P, promotes cancer
cell aggressiveness in other cellular systems [50]. Therefore, we tested the influence of
C1P in prostate cancer cell function. First, we generated spheroids of LNCaP cells. These
spheroids were embedded in collagen, challenged with vehicle or C1P (20 µM), and the
increase in the total area of the structure was evaluated 7 days later. Interestingly, C1P
treatment did not influence two-dimensional cell growth but increased spheroid diameter
(Figure 4A,B). Second, C1P treatment (20 µM) slightly increased the migration of LNCaP
cells in wound healing assays (Figure 4C). Third, we performed transwell migration assays
in a migratory prostate cancer cell line, namely PC3. C1P elicited a time-dependent increase
in cell migration, over a monitored period of 72 h (Figure 4D). As a control of this assay,
we tested the effect of the non-phosphorylated counterpart (C2-Ceramide, C2C) on PC3
cells. As reported [50] we corroborated the growth-suppressive activity of this sphingolipid
(Figure S5A,B).
To further ascertain the role of CERK in PCa cell biology we set up genetic manipula-
tion tools to perturb CERK expression. We chose to silence CERK in PCa cells with high and
low expression of this gene, PC3 and LNCaP, respectively. We generated two independent
inducible lentiviral shRNA sequences that efficiently reduced CERK mRNA abundance
(Figure S5C). In agreement with our C1P supplementation results, CERK silencing reduced
aggressive properties without affecting cell proliferation in PC3 cells, but had no functional
consequences in CERK low expressing cells, LNCaP (Figure S5D,E).
These results reinforce the notion that ceramide phosphorylation by CERK could have
a biological impact on prostate cancer cells.




Figure 4. C1P promotes prostate cancer cell migration and invasive growth. (A) Proliferation upon treatment with 20 µM 
ceramide-1-phosphate (C1P) in LNCaP cells (n = 3 independent experiments). Paired t-test. Comparisons made versus 
vehicles. (B) Quantification of spheroid diameter increase upon treatment with 20 µM C1P in LNCaP cells compared to 
vehicle (Veh) (n = 6 independent experiments), one-sample t-test, and representative images of the spheroids at seeding 
and the end of the experiment. (C) Quantification of wound healing migration assay upon treatment with 20 µM C1P in 
LNCaP cells compared to vehicle (Veh) (n = 3 independent experiments, paired t-test), and representative images of the 
wound area at seeding and at the different measured time points. (D) Quantification and representative images of cell 
Figure 4. C1P promotes prostate cancer cell migration and invasive growth. (A) Proliferation upon treatment with 20 µM
ceramide-1-phosphate (C1P) in LNCaP cells (n = 3 independent experiments). Paired t-test. Comparisons made versus
vehicles. (B) Quantification of spheroid diameter increase upon treatment with 20 µM C1P in LNCaP cells compared to
vehicle (Veh) (n = 6 independent experiments), one-sample t-test, and representative images of the spheroids at seeding and
the e of the experim nt. (C) Quantification of w und healing migration assay upon treatment with 20 µM C1P in LNCaP
cells compar d to vehicl (Veh) (n = 3 independent experiments, aired t- est), an representative images of the wound ar a
at seeding and at the different measured time points. (D) Quantification and representative images of cell migration upon
treatment with 20 µM C1P in PC3 cells compared to vehicle (Veh) (n = 4 independent experiments). Unpaired t-test. All
comparisons are two-tailed. * p < 0.05; ** p < 0.01.
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3. Discussion
The signaling cascade regulated by AR is essential for the function of prostate cells [6,7,9].
The studies of AR transcriptional regulation were limited to a few AR-target genes but
thanks to the advances in high-throughput genomic technologies, now we know that this
nuclear receptor regulates the expression of more than 1500 genes [15,47]. Androgen-bound
AR is primarily known as a transcription activator but additional evidence shows that it
can also repress gene expression [16,17]. Only a handful of genes have been molecularly
characterized as directly repressed by AR [17,45,51]. In this context, our results provide
detailed molecular regulation of a gene repressed by AR, with validations that encompass
human specimens, murine models, and cellular systems. In turn, our work, together with
previous studies by other groups, encourages a more extensive analysis of the molecular
determinants of AR-elicited transcriptional activation vs. repression.
Lipid uptake and metabolism is under the control of androgen signaling [20,52–57].
In fact, elevated lipid biosynthesis has been postulated to promote the development of
castration-resistant PCa [52,54], and inhibition of fatty acid synthase has been proposed
as a therapeutic strategy to target this pathological state [53]. Despite the vast knowledge
around lipid metabolism regulation by androgens, the information around the role and rele-
vance of these hormones in the control of sphingolipid metabolism is limited. Sphingolipid
metabolism produces metabolites that influence multiple biological processes [26,58,59].
Phosphorylation of ceramide species illustrates the dichotomy of sphingolipids in the
regulation of cell survival and motility vis a vis cell death [50,60]. In this regard, CERK
activity is predicted to support cell viability, with an increase in the pool of phosphorylated
ceramide. Our results corroborate that C1P can promote prostate cancer cell aggressiveness.
Since AR represses CERK, the functional outcome of this regulation would be a decrease in
C1P. Conversely, our results suggest that loss of AR signaling derepresses CERK and leads
to the elevation of C1P, which could counteract the therapeutic effect of AR antagonists
and uncover a mechanism for the development of castration-resistant PCa. Moreover, this
increase in CERK levels could represent an unprecedented target to curb prostate cancer
aggressiveness, as demonstrated in AR-negative PC3 cells. The specific pathophysiological
context in which this regulation be therapeutically exploited remains to be defined.
EZH2 is an epigenetic modifier that is overexpressed in multiple cancer types [61]. In
PCa, this gene is associated with disease progression and metastasis [49], and the crosstalk
between AR and this factor has been previously reported [45,62–64]. Interestingly, we
report that EZH2 represses CERK. EZH2 inhibitor GSK126 elicited robust activation of
CERK expression, and combination with AR agonists and antagonists interfered with the
repressive activity of androgen signaling on this gene. Moreover, EZH2 interacted with the
androgen receptor site in CERK regulatory region. Our analysis of CERK and EZH2 gene
expression in PCa datasets suggests that the action of the epigenetic modifier on CERK
might be operational beyond the context of AR. In turn, our results open a new area for the
study of Polycomb group proteins in the control of sphingolipid metabolism.
4. Materials and Methods
4.1. Cell Culture
Human prostate cancer cell lines PC3, DU145, LNCaP and the benign prostate hyper-
plasia cell line BPH1 were purchased from Leibniz Institut DSMZ (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH), who provided authentication certificate.
Human prostate cancer cell lines 22RV1 and VCaP were purchased from American Type
Culture Collection (ATCC). Human prostate cancer cell line C4-2, and human prostatic
epithelial cell lines PWR1E and RWPE1 were generously provided by the laboratory of Dr.
Pier Paolo Pandolfi. Cell lines were periodically subjected to microsatellite-based identity
validation. The cell lines used in this study were not found in the database of commonly
misidentified cell lines maintained by ICLAC and NCBI Biosample. All cell lines were
routinely monitored for mycoplasma contamination. DU145, PC3, and VCaP cell lines were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) while LNCaP, C4-2, and 22RV1
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cell lines were maintained in regular Roswell Park Memorial Institute (RPMI) medium
without any supplement except for complete 10% (v/v) fetal bovine serum (FBS, Gibco) and
1% (v/v) penicillin-streptomycin (Gibco). PWR1E and RWPE1 cell lines were maintained
in Keratinocyte Serum-Free Medium (K-SFM; Gibco) supplemented with 0.05 mg/mL
bovine pituitary extract (BPE; Gibco) and 5 ng/mL epidermal growth factor (EGF; Gibco).
BPH1 was maintained in RPMI medium supplemented with 20% FBS, 20 ng/mL DHT,
5 ug/mL transferrin, 5 µg/mL insulin, and 5 ng/mL sodium selenite (all supplements
from Sigma-Aldrich St. Louis, MO, USA).
4.2. Generation of Stable Cell Lines
293FT cells were used for lentiviral production. Lentiviral vectors expressing vali-
dated shRNAs against human CERK from the Mission shRNA Library were subcloned
in a Plko Tet on inducible system (following the strategy provided by Dr. Dmitri Wieder-
schain [65], Addgene plasmid # 21915). Cells were transfected with lentiviral vectors
following standard procedures, and viral supernatant was used to infect cells. The se-
lection was done using puromycin (2 µg/mL) for 48 h. As a control, a lentivirus with
scrambled shRNA (shC) was used. (Short hairpins sequences: sh88: CCGGGCCACGATG-
GATCGCTGGTTTCTCGAGAAACCAGCGATCCATCGTG GCTTTTTG, sh89: CCGGCG-
GCTTAAACTTTGATCTGTACTCGAGTACAGA TCAAAGTTTAAGC CGTTTTTTG, shC:
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTG TTG.
4.3. Reagents
DHT (4,5α-Dihydrotestosterone) was purchased from Sigma-Aldrich (St. Louis, MO,
USA; A8380) and dissolved in ethanol at 10 µM to be used at a final concentration of 10 nM.
MDV3100 (enzalutamide), from Santa Cruz Biotechnology (Dallas, TX, USA; sc-364354),
was diluted in DMSO at 10 mM and used at 10µM. GSK126 (EZH2 inhibitor) was pur-
chased from MedChemExpress (Monmouth Junction, NJ, USA; HY-13470), dissolved
in DMSO, and used in a range of concentrations for 24 h. C2 Ceramide (N-acetoyl-D-
erythro-sphingosine) was purchased from Avanti Polar Lipids (Alabaster, AL, US; 860502),
dissolved in DMSO, and used at a final concentration of 20 µM. Doxycycline Hyclate
(Dox, used at a final concentration of 0.25 µg/mL) and C16 Ceramide 1-phosphate (C1P,
860533P) were purchased from Sigma Aldrich (St. Louis, MO, US). An aqueous dispersion
(in the form of liposomes) was prepared by sonicating C1P (1 mg) in sterile nanopure
water (600 µL) on ice using a probe sonicator for six cycles of 8 s on and 5 s off until a
clear dispersion was obtained. C1P concentration in the stock solution was 2.6 mM and
a final concentration of 20 µM was used for all cellular assays. This procedure is consid-
ered preferable to C1P dispersions in organic solvents because lipid droplet formation is
minimized and exposure of cells to alcohols or dodecane is avoided.
4.4. Animals
Prostate epithelium-specific deletion Pten knockout (C57/BL6/129sv; Pb-Cre4; Pten
lox/lox) model was kindly provided by Dr. Pandolfi. All mouse experiments were carried
out following the ethical guidelines established by the Biosafety and Welfare Committee at
CIC bioGUNE (Spanish acronym for center for cooperative research in Biosciences). The
procedures employed were carried out following the recommendations from AAALAC
(Association for Assessment and Accreditation of Laboratory Animal Care). Orchiectomy
was performed in 4 months Ptenpc+/+ mice and 6 months Ptenpc−/− mice, and 6 days later
prostate lobules were collected. Mice were fasted for 6 h prior to tissue harvest to prevent
metabolic alterations due to immediate food intake.
4.5. qRTPCR
RNA was extracted using a NucleoSpin® RNA isolation kit (Macherey-Nagel, Dueren,
Germany; 740955.240C). For animal tissues, a Trizol-based implementation of the NucleoSpin®
RNA isolation kit protocol (Provided above) was used as referenced [66]. For all cases,
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1 µg of total RNA was used for cDNA synthesis using Maxima™ H Minus cDNA Syn-
thesis Master Mix (ThermoFisher, Waltham, MA, US; M1682). Quantitative Real-Time
PCR (qRTPCR) was performed as previously described [67]. Universal Probe Library
(Roche, Basel, Switzerland) primers and probes employed (Roche; ThermoFisher) are
detailed in Table S1. All qRTPCR data presented was normalized using GAPDH/Gapdh
(ThermoFisher; Hs02758991_g1, Mm99999915_g1).
4.6. Sphingolipid Metabolic Analysis
LNCaP cells were treated with vehicle or MDV for 24 h and two million cells per
condition were washed, pelleted and sent for analysis. Internal standards were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA) and were added to samples in 10 µL
ethanol:methanol:water (7:2:1) as a cocktail of 250 pmol each. Standards for sphingoid bases
and sphingoid base 1-phosphates were 17-carbon chain length analogs: C17-sphingosine,
(2S,3R,4E)-2-aminoheptadec-4-ene-1,3-diol (d17:1-So); C17-sphinganine, (2S,3R)-2-
aminoheptadecane-1,3-diol (d17:0-Sa); C17-sphingosine 1-phosphate, heptadecasphing-4-
enine-1-phosphate (d17:1-So1P); and C17-sphinganine 1-phosphate, heptadecasphinganine-
1-phosphate (d17:0-Sa1P). Standards for N-acyl sphingolipids were C12-fatty acid analogs:
C12-Cer, N-(dodecanoyl)-sphing-4-enine (d18:1/C12:0); C12-Cer 1-phosphate, N-(dodecanoyl)-
sphing-4-enine-1-phosphate (d18:1/C12:0-Cer1P); C12-sphingomyelin, N-(dodecanoyl)-
sphing-4-enine-1-phosphocholine (d18:1/C12:0-SM); and C12-glucosylceramide, N-
(dodecanoyl)-1-β-glucosyl-sphing-4-eine.
Sample homogenates were collected into 13 × 100 mm borosilicate tubes with a
Teflon-lined cap (catalog #60827-453, VWR, West Chester, PA, USA). Then 2 mL of CH3OH
and 1 mL of CHCl3 were added along with the internal standard cocktail (250 pmol of
each species dissolved in a final total volume of 10 µL of ethanol:methanol:water 7:2:1).
The contents were dispersed using an ultra sonicator at room temperature for 30 s. This
single-phase mixture was incubated at 48 ◦C overnight. After cooling, 150 µL of 1 M
KOH in CH3OH was added and, after brief sonication, incubated in a shaking water bath
for 2 h at 37 ◦C to cleave potentially interfering glycerolipids. The extract was brought
to neutral pH with 12 µL of glacial acetic acid, then the extract was centrifuged using a
table-top centrifuge, and the supernatant was removed by a Pasteur pipette and transferred
to a new tube. The extract was reduced to dryness using a Speed Vac. The dried residue
was reconstituted in 0.5 mL of the starting mobile phase solvent for LC-MS/MS analysis,
sonicated for ca 15 s, then centrifuged for 5 min in a tabletop centrifuge before the transfer
of the clear supernatant to the autoinjector vial for analysis.
For LC-MS/MS analyses, a Shimadzu Nexera LC-30 AD binary pump system coupled
to a SIL-30AC autoinjector and DGU20A5R degasser coupled to an AB Sciex
5500 quadrupole/linear ion trap (QTrap) (SCIEX, Framingham, MA, USA) operating
in a triple quadrupole mode was used. Q1 and Q3 were set to pass molecularly distinctive
precursor and product ions (or a scan across multiple m/z in Q1 or Q3), using N2 to
collisionally induce dissociations in Q2 (which was offset from Q1 by 30–120 eV); the ion
source temperature set to 500 ◦C.
The compounds were separated by reverse-phase LC using a Supelco 2.1 (i.d.) × 50 mm
Ascentis Express C18 column (Sigma, St. Louis, MO, USA) and a binary solvent system at
a flow rate of 0.5 mL/min with a column oven set to 35 ◦C. Prior to injection of the sample,
the column was equilibrated for 0.5 min with a solvent mixture of 95% Moble phase A1
(CH3OH/H2O/HCOOH, 58/41/1, v/v/v, with 5 mM ammonium formate) and 5% Mobile
phase B1 (CH3OH/HCOOH, 99/1, v/v, with 5 mM ammonium formate), and after sample
injection (typically 40 µL), the A1/B1 ratio was maintained at 95/5 for 2.25 min, followed
by a linear gradient to 100% B1 over 1.5 min, which was held at 100% B1 for 5.5 min,
followed by a 0.5 min gradient return to 95/5 A1/B1. The column was re-equilibrated with
95:5 A1/B1 for 0.5 min before the next run.
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4.7. ChIP
Chromatin Immunoprecipitation (ChIP) was performed using the SimpleChIP® En-
zymatic Chromatin IP Kit (Cell Signalling Technology, Inc, Danvers, MA, USA; 9003)
following the manufacturer’s instructions. Three million LNCaP cells were seeded in
150 mm dishes. Three days later each dish containing 20 mL medium was treated with ve-
hicle or DHT for 4 h and then was cross-linked with 540 µL 35% formaldehyde for 10 min at
room temperature. Glycine was added to dishes, and cells were incubated for 5 min at room
temperature. Cells were then washed twice with ice-cold PBS and scraped into PBS + PIC
(Protease Inhibitor Cocktail). Pelleted cells were lysed and nuclei were harvested. Nuclear
lysates were digested with micrococcal nuclease for 20 min at 37 ◦C and then sonicated
in 500 µL aliquots on ice for 6 pulses of 20 s (with 20 s gaps) using a Branson sonicator.
Lysates were clarified at 10,000× g for 10 min at 4 ◦C, and chromatin was stored at −80 ◦C.
Androgen Receptor polyclonal rabbit antibody (Santa Cruz Biotechnology, Dallas, TX, USA;
D2C9), EZH2 monoclonal rabbit antibody (Cell Signaling Technology, Danvers, MA, USA;
N-20), and IgG antibody (Cell Signalling Technology, Inc, Danvers, MA, USA; 2729), were
incubated overnight at 4 ◦C with rotation and protein G magnetic beads were incubated
2 h at 4 ◦C. Washes and elution of chromatin were performed following the manufacturer’s
instructions. DNA quantification was carried out using a Viia7 Real-Time PCR System
(ThermoFisher, Waltham, MA, USA) with SYBR-Green reagents and primers that amplify
Androgen Receptor sites (AR sites) present in CERK sequence as well as KLK3 enhancer
region [68] as control (detailed in Table S3).
4.8. Cellular Assays
4.8.1. Cell Growth Analysis
15,000 PC3 cells or 30,000 LNCaP cells were plated in triplicate in 12-well dishes.
Twenty-four hours later, the cells considered day 0 were fixed in formalin 10%. The same
procedure was performed on the days indicated in Figure 4A and Figure S5. Cell growth
was measured by staining with crystal violet (0.1% in 20% methanol) for 45 min. The
precipitate was solubilized in 10% acetic acid, and the absorbance was measured at 595 nm.
4.8.2. Invasive Growth
40,000 cells were resuspended in 1ml RPMI with 6 % methylcellulose (Sigma-Aldrich
St. Louis, MO, USA; M0387). Drops (25 µL) were pipetted on the cover of a 100 mm culture
plate. The inverted plates were incubated at 37 ◦C and 5% CO2 for 72 h. Once formed,
spheroids were collected, resuspended in collagen I solution (1.7 mg/mL in DMEM) with or
without 20 µM C1P, and seeded in a 24-well plate. Day 0 pictures were taken and complete
RPMI media was then added on top of the collagen. Spheroids were maintained at 37 ◦C
and 5% CO2 for 7 days and pictures were again taken. The area of the spheroids was
measured using FiJi software. Relative invasive growth was quantified as area difference
on day 7 minus day 0.
4.8.3. Wound Healing
600,000 LNCaP cells were plated in duplicates in 6-well plates, grown to confluency,
and the cell monolayer was wounded with a pipette tip. Photomicrographs of each scratch
were obtained at the initial time of wound creation and the same location was photographed
every 24 h until completion of the study. Fiji software was used to quantify the area of the
wound remaining. This number was then converted to a percentage of the scratch area
remaining at each time point.
4.8.4. Migration
24-well plates with 8 µm pore size chambers (Corning Costar #3422) were precoated
with 30 µL of fibronectin (0.2 µg/µL dH2O, Sigma, St. Louis, MO, US; F2006). Cells
(50,000 in 100 µL per insert) were resuspended in a medium supplemented with 0.2% fatty
acid-free bovine serum albumin (BSA) and seeded in duplicates to the upper part of the
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chamber of 24-well plates. 300 µL media with 0.2% BSA with or without 20 µM C1P was
added to the lower wells. After the corresponding incubation time (8 to 72 h) at 37 ◦C
and 5% CO2, chambers were washed and non-migrated cells were removed with a cotton
swab. Filters were fixed with formaldehyde (5% in PBS) and stained with 0.1% crystal
violet. Cell migration was assessed by counting the number of migrated cells in a Nikon
Eclipse 90i microscope equipped with NIS-Elements 3.0 software. Cells were counted in
eight randomly selected microscope fields per filter at 20x magnification.
4.8.5. Anchorage-Independent Growth
6 well-plates were coated with a lower layer of 0.6% agar (SeaKem LE agarose, Lonza,
Basel, Switzerland) medium mixture (3 mL/well) and stored at 4 ◦C for at least 30 min to
let the agar solidify. 5000 PC3 cells or 15,000 LNCaP cells per well were suspended in a
0.3% low melting agar (Agarose LM, Pronadisa, Conda, Madrid, Spain) medium mixture
and 1 mL/well were plated in duplicates. Plates were stored at 4 ◦C (around 30 min) to
allow the solidification of the upper layer and then incubated at 37 ◦C in a humidified
atmosphere of 5% CO2 for 3–4 weeks, until colony detection. Colonies were then quantified
using Fiji software (ImageJ version 1.53c).
4.9. Bioinformatics Analysis and Statistics
Correlations and enrichment bioinformatics analysis were performed with Cancer-
tool [28]. No statistical method was used to predetermine sample size. The experiments
were not randomized. The investigators were not blinded to allocation during experiments
and outcome assessment. n values represent the number of independent experiments
performed or the number of individual mice. For each independent in vitro experiment,
at least two technical replicates were used and a minimum number of three experiments
were performed to ensure adequate statistical power. For in vitro experiments normal
distribution was assumed. One sample t-test was applied for one component comparisons
with control when one of the two groups did not have a variance and paired t-test for
matched data in each experiment. One-way ANOVA was used for multiple comparisons.
For in vivo experiments a non-parametric Mann–Whitney exact test was used. Unless
otherwise stated, data analyzed by parametric tests are represented by the mean ± s.e.m.
of pooled experiments and median ± interquartile range for experiments analyzed by
non-parametric tests. Two-tail statistical analysis was applied for experimental design
without predicted result and one-tail for validation or hypothesis-driven experiments. The
confidence level used for all the statistical analyses was 95% (alpha value = 0.05). GraphPad
Prism 8 software was used for statistical calculations.
5. Conclusions
In this study, we demonstrate the potential of computational analysis using publicly
available transcriptional datasets to identify novel metabolic targets of AR in prostate
cancer. The repressive control of ceramide kinase by this nuclear receptor exemplifies the
complex functions of hormone signaling in this disease.
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